Archive · 12 Nov 2025
Aarti Drugs Q2 Earnings Show Profit Growth; CFO Eyes Rs 3,500 Crore Sales
Aarti Drugs, a pharmaceutical company, announced its earnings for the second quarter.
Their profit went up by almost 30% compared to last year.
Their sales also increased.
The company's finance boss thinks they can make about 3,500 crore rupees in sales in the next few years.
He also believes their profit margins can get better, reaching between 15% and 16%.
This improvement is expected because they are increasing their production capacity and working on making their manufacturing processes more efficient, including saving energy.
The company's stock was trading steadily on Wednesday.
Aarti Drugs reported a 29% year-over-year increase in net profit to Rs 45.28 crore for Q2.
Revenue for Q2 rose by 9.1% to Rs 652.8 crore compared to the previous year.
EBITDA increased by 25.8% to Rs 84.28 crore in Q2, with EBITDA margins at 12.91%.
The company's CFO projects sales to reach Rs 3,200-3,500 crore within two to three years.
Aarti Drugs aims to achieve EBITDA margins between 15% and 16% through capacity expansion and process improvements.
- Who
- Aarti Drugs and its CFO Adhish Patil
- What
- Reported a 29% rise in net profit for Q2 and provided future sales and EBITDA margin projections.
- When
- Q2 earnings report and ongoing discussions
- Where
- India (implied by company and currency)
- Why
- To update stakeholders on financial performance and future growth strategy.
- Q2 Net Profit
- Rs 45.28 crore (up 29% YoY)
- Q2 Revenue
- Rs 652.8 crore (up 9.1% YoY)
- Q2 EBITDA
- Rs 84.28 crore (up 25.8% YoY)
- Q2 EBITDA Margins
- 12.91%
- Projected Sales Target
- Rs 3,200 - Rs 3,500 crore in 2-3 years
- Projected EBITDA Margins
- 15-16%
- Market Cap
- Rs 4,323 crore